Aktienanalyse zu Champions Oncology Inc (CSBR)CSBRChampions Oncology Inc

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Its pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development. The Company operates in one segment pertaining to oncology services. Its research platform is a proprietary bank of Patient Derived Xenograft (PDX) models. Its PDX models are deployed into advanced vivo and ex vivo pharmacology platforms, providing an insight into therapeutic programs. The PDX bank is characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of data for its oncology dataset. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Champions Oncology Inc (CSBR) is currently priced at $4.81, which is near the 52-week low of $4.59. The stock has a forward P/E ratio of 22.88, indicating potential for growth, but it has experienced a significant year-to-date decline of 27.78%. The RSI is at 47.60, suggesting the stock is neither overbought nor oversold. The main risk is its negative net income trend, with a net loss of $667,000 in the last quarter, which raises concerns about profitability moving forward.

1 analysts cover CSBR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.